KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.80

Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial.

Andrzej Nowojewski, Alex Wheal, William Dott, Dario Ruscica, Serban Ghiorghiu, Barbara Valastro

BMJ Open 15(10) e094596

PMID41151963
PMCIDPMC12570934
DOI10.1136/bmjopen-2024-094596
发表日期2025-10-28
入排依据:The record describes a secondary analysis of participant experience in a Phase III randomized oncology trial. While the trial itself is oncology, human, randomized, and Phase III, the specific publication is focused on implementing a feedback questionnaire (quality-of-life/psychosocial measure) and does not report on a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or drug intervention details for this analysis. The deterministic review correctly flagged the absence of a time-to-event signal.
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。
摘要

摘要

OBJECTIVES: To understand participant experience in the INTERLINK-1 clinical trial using the Study Participant Feedback Questionnaire (SPFQ), explore factors associated with participant experience and evaluate the implementation of the SPFQ. DESIGN: Phase 3, randomised, double-blind, placebo-controlled, multicentre trial. SETTING: 79 sites in 21 countries from October 2020 to October 2022. PARTICIPANTS: 371 adults with recurrent/metastatic head and neck squamous cell carcinoma (39% aged >66 years, 69% White and 81% male). PRIMARY OUTCOME MEASURES: SPFQ administered at enrolment (SPFQ-A), during the trial (SPFQ-B) and at trial completion (SPFQ-C). RESULTS: A total of 223, 64 and 93 participants completed the SPFQ-A, SPFQ-B and SPFQ-C, respectively. Early termination of the INTERLINK-1 study limited the number of SPFQ-B and SPFQ-C responses. For all but one question, over 80% of participants selected positive responses, indicating positive experience with regards to enrolment (SPFQ-A), site (SPFQ-B) and overall trial (SPFQ-C). Individually, quality of life, continent and race were significantly associated with participant experience. Small numbers of negative and neutral responses enabled the construction of multiple ordinal regression models and were used to identify unbiased coefficients associated with patient experience. The models showed that males and participants in Asia reported worse experiences in questions regarding trial enrolment (p<0.05). Recent adverse events and higher Eastern Cooperative Oncology Group (ECOG) performance status were significantly negatively associated with trial site satisfaction (B1; OR 0.24, 95% CI 0.06 to 0.96, p<0.05) and site staff-related questions (B5; OR 0.18, 95% CI 0.04 to 0.93, p<0.05), respectively. Indications of acquiescence bias were found, possibly due to SPFQ question design. CONCLUSIONS: Overall, participants reported positive experiences in the INTERLINK-1 study as evaluated by the SPFQ. Specific aspects of participant experience varied by sex, continent, recent adverse events and ECOG status. Further investigation is required to understand the causes of these findings to develop strategies for improved participant experience. Observations from this study will be used to inform future SPFQ implementation and develop strategies for better, more equitable trial experiences. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT04590963.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Overall SPFQ response distribution. Questions B7, B8, C1 and C2 used a yes/no scale, represented by dark blue and dark red colours and dotted texture. Question C5 used a reverse valence scale, but it is represented here with a striped texture to match the responses in other questions in this graph (eg, dark blue means ‘Much less than expected,’ dark red ‘Much more than expected’). SPFQ, Study Participant Feedback Questionnaire.
非 KM Figure